Briquilimab's CSU efficacy data set the stage for Phase 2b, but a distressed strategic review may prevent Jasper from running it independently

Bull

A partner, acquirer, or new financing enables Phase 2b to commence as planned, validating the CSU efficacy signal from BEACON and the OLE (67% complete response, mean UAS7 reduction of 31 points) as commercially credible. Study initiation would confirm that the dose selection work is accepted by FDA and that the program has a viable path to a pivotal dataset, materially increasing briquilimab's licensing or acquisition value and supporting the thesis that the asset can be developed through to approval.

Bear

The strategic alternatives process concludes without a partner or acquirer willing to fund Phase 2b, forcing an orderly wind-down before the study can begin. The most likely failure modes are insufficient cash runway — with only $14.1M on hand against ~$10.9M quarterly burn — and a market perception that the Phase 2a dataset (small n=6 cohort for the key dose) is too thin to justify a full Phase 2b commitment without additional de-risking capital that Jasper cannot independently raise.